Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Opthea Licenses Selexis’ CHO-M Cell Line | Contract Pharma

What are you searching for?

Sign in
Breaking News

Opthea Licenses Selexis’ CHO-M Cell Line

To produce OPT-302 for Phase I trial in wet AMD

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Opthea Pty Ltd. has entered into a commercial license agreement with Selexis SA to use its CHO-M Cell Line and related technologies for the production of OPT-302, an Fc fusion protein for the treatment of wet Age-Related Macular Degeneration (wet AMD). OPT-302 is scheduled to enter Phase I studies in early 2015 and is being developed by Opthea, a subsidiary of Circadian Technologies of Melbourne, Australia.
 
“Selexis is excited about the collaboration with Opthea and looks forward to seeing OPT-302 progress to clinical studies in wet AMD patients,” said Dr. Igor Fisch, chief executive officer, Selexis SA. “The OPT-302 cell line demonstrates the power of our new technologies for the rapid generation of CHO cell lines expressing high yields of Fc fusion recombinant proteins. We look forward to continuing to work with Opthea.”
 
“The productivity and speed of stable cell line generation with the SUREtechnology Platform is playing a key role in quickly progressing our candidate into clinical development,” said Dr. Megan Baldwin, chief executive officer of Opthea. “By leveraging the SUREtechnology Platform, we were able to improve our titers by several fold.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics